| 000 | 01808 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517131505.0 | ||
| 264 | 0 | _c20180221 | |
| 008 | 201802s 0 0 eng d | ||
| 022 | _a1521-009X | ||
| 024 | 7 |
_a10.1124/dmd.116.071613 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiu, Hong | |
| 245 | 0 | 0 |
_aMetabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites. _h[electronic resource] |
| 260 |
_bDrug metabolism and disposition: the biological fate of chemicals _c03 2017 |
||
| 300 |
_a294-305 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAbsorption, Physiological |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xblood |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 |
_aBridged Bicyclo Compounds, Heterocyclic _xblood |
| 650 | 0 | 4 |
_aFeces _xchemistry |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-bcl-2 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSulfonamides _xblood |
| 650 | 0 | 4 | _aTissue Distribution |
| 700 | 1 | _aMichmerhuizen, Melissa J | |
| 700 | 1 | _aLao, Yanbin | |
| 700 | 1 | _aWan, Katty | |
| 700 | 1 | _aSalem, Ahmed Hamed | |
| 700 | 1 | _aSawicki, James | |
| 700 | 1 | _aSerby, Michael | |
| 700 | 1 | _aVaidyanathan, Srirajan | |
| 700 | 1 | _aWong, Shekman L | |
| 700 | 1 | _aAgarwal, Suresh | |
| 700 | 1 | _aDunbar, Martin | |
| 700 | 1 | _aSydor, Jens | |
| 700 | 1 | _ade Morais, Sonia M | |
| 700 | 1 | _aLee, Anthony J | |
| 773 | 0 |
_tDrug metabolism and disposition: the biological fate of chemicals _gvol. 45 _gno. 3 _gp. 294-305 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1124/dmd.116.071613 _zAvailable from publisher's website |
| 999 |
_c26712938 _d26712938 |
||